ASH 2015 | Improving patient outcomes in acute lymphoblastic leukemia at ASH 2015

Ryan Cassaday

Ryan Cassaday, MD, from Fred Hutchinson Cancer Research Center, Seattle, WA, discusses clinical data presented on acute lymphoblastic leukemia (ALL) at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition. Highlights include a clinical trial evaluating rituximab, an anti-CD20 monoclonal antibody, added to a chemotherapy backbone; a phase 2 clinical trial of blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen; and early clinical trials evaluating CD19-targeted chimeric antigen receptor (CAR) T-cell therapy.

Share this video